Cargando…
Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity
BACKGROUND: Decision analyses of drug treatments in chronic diseases require modeling the progression of disease and treatment response beyond the time horizon of clinical or epidemiological studies. In many such models, progression and drug effect have been applied uniformly to all patients; hetero...
Autores principales: | Siebert, Uwe, Sroczynski, Gaby, Zietemann, Vera |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
German Medical Science GMS Publishing House
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011301/ https://www.ncbi.nlm.nih.gov/pubmed/21289909 |
Ejemplares similares
-
Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment
por: Siebert, Uwe, et al.
Publicado: (2003) -
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
por: Mühlberger, Nikolai, et al.
Publicado: (2009) -
Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
por: Hallsson, Lára R., et al.
Publicado: (2023) -
Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer—A Systematic Review
por: Sroczynski, Gaby, et al.
Publicado: (2020) -
Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR
por: Hoffmann, Sabine, et al.
Publicado: (2020)